Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy

Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.

Black swan
Pfizer adds asset in rare diseases • Source: Shutterstock

Pfizer Inc. is to pay $810m to buy Swiss rare disease company Therachon AG, to obtain its asset TA-46 for achondroplasia, the most common form of short-limbed dwarfism.

The deal terms mean that Pfizer will pay $340m upfront, with an added $470m in additional payments dependent on TA-46...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip